Skip to main content

Table 1 Estimated mean disability-adjusted life years (DALYs) lost on a per-capita basis as a result of onchocercal blindness, skin disease, and L. loa encephalopathy, under conditions of: 1) no mass treatment with Mectizan®; 2) mass treatment with no risk reduction strategy; and 3) mass treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40 to reduce risk of L. loa encephalopathy. DALYs are expressed as mean years lost per person for the entire population. Four scenarios are considered based on high and low prevalence of loiasis and onchocerciasis, respectively (as defined in the Appendix - see additional file 1).

From: A Framework for Decision-Making for Mass Distribution of Mectizan® in Areas Endemic for Loa loa

Loiasis Prevalence

High

High

Low

Low

Onchocerciasis Prevalence

High

Low

High

Low

No Mectizan® treatment

1.5155

0.8822

1.5155

0.8822

Mectizan® treatment

    

   No risk reduction strategy

0.5319

0.3102

0.5309

0.3092

   REA

0.5393

0.3436

0.5391

0.3436

   RAPLOA-40

0.5307

0.3090

0.5305

0.3088

   RAPLOA-20

0.5305

0.3088

0.5305

0.3088

   REA/RAPLOA-40

0.5341

0.3228

0.5313

0.3124